BACKGROUND: Orthopaedic biomaterials are susceptible to biofilm formation. A novel lipid-based material has been developed that may be loaded with antibiotics and applied as an implant coating at point of care. However, this material has not been evaluated for antibiotic elution, biofilm inhibition, or in vivo efficacy. QUESTIONS/PURPOSES: (1) Do antibiotic-loaded coatings inhibit biofilm formation? (2) Is the coating effective in preventing biofilm in vivo? METHODS: Purified phosphatidylcholine was mixed with 25% amikacin or vancomycin or a combination of 12.5% of both. A 7-day elution study for coated titanium and stainless steel coupons was followed by turbidity and zone of inhibition assays against Staphylococcus aureus and Pseudomonas aeruginosa. Coupons were inoculated with bacteria and incubated 24 hours (N = 4 for each test group). Microscopic images of biofilm were obtained. After washing and vortexing, attached bacteria were counted. A mouse biofilm model was modified to include coated and uncoated stainless steel wires inserted into the lumens of catheters inoculated with a mixture of S aureus or P aeruginosa. Colony-forming unit counts (N = 10) and scanning electron microscopy imaging of implants were used to determine antimicrobial activity. RESULTS: Active antibiotics with colony inhibition effects were eluted for up to 6 days. Antibiotic-loaded coatings inhibited biofilm formation on in vitro coupons (log-fold reductions of 4.3 ± 0.4 in S aureus and 3.1 ± 0 for P aeruginosa in phosphatidylcholine-only coatings, 5.6 ± 0 for S aureus and 3.1 ± 0 for P aeruginosa for combination-loaded coatings, 5.5 ± 0.3 for S aureus in vancomycin-loaded coatings, and 3.1 ± 0 for P aeruginosa for amikacin-loaded coatings (p < 0.001 for all comparisons of antibiotic-loaded coatings against uncoated controls for both bacterial strains, p < 0.001 for comparison of antibiotic-loaded coatings against phosphatidylcholine only for S aureus, p = 0.54 for comparison of vancomycin versus combination coating in S aureus, P = 0.99 for comparison of antibiotic- and unloaded phosphatidylcholine coatings in P aeruginosa). Similarly, antibiotic-loaded coatings reduced attachment of bacteria to wires in vivo (log-fold reduction of 2.54 ± 0; p < 0.001 for S aureus and 0.83 ± 0.3; p = 0.112 for P aeruginosa). CONCLUSIONS: Coatings deliver active antibiotics locally to inhibit biofilm formation and bacterial growth in vivo. Future evaluations will include orthopaedic preclinical models to confirm therapeutic efficacy. CLINICAL RELEVANCE: Clinical applications of local drug delivery coating could reduce the rate of implant-associated infections.
BACKGROUND: Orthopaedic biomaterials are susceptible to biofilm formation. A novel lipid-based material has been developed that may be loaded with antibiotics and applied as an implant coating at point of care. However, this material has not been evaluated for antibiotic elution, biofilm inhibition, or in vivo efficacy. QUESTIONS/PURPOSES: (1) Do antibiotic-loaded coatings inhibit biofilm formation? (2) Is the coating effective in preventing biofilm in vivo? METHODS: Purified phosphatidylcholine was mixed with 25% amikacin or vancomycin or a combination of 12.5% of both. A 7-day elution study for coated titanium and stainless steel coupons was followed by turbidity and zone of inhibition assays against Staphylococcus aureus and Pseudomonas aeruginosa. Coupons were inoculated with bacteria and incubated 24 hours (N = 4 for each test group). Microscopic images of biofilm were obtained. After washing and vortexing, attached bacteria were counted. A mouse biofilm model was modified to include coated and uncoated stainless steel wires inserted into the lumens of catheters inoculated with a mixture of S aureus or P aeruginosa. Colony-forming unit counts (N = 10) and scanning electron microscopy imaging of implants were used to determine antimicrobial activity. RESULTS: Active antibiotics with colony inhibition effects were eluted for up to 6 days. Antibiotic-loaded coatings inhibited biofilm formation on in vitro coupons (log-fold reductions of 4.3 ± 0.4 in S aureus and 3.1 ± 0 for P aeruginosa in phosphatidylcholine-only coatings, 5.6 ± 0 for S aureus and 3.1 ± 0 for P aeruginosa for combination-loaded coatings, 5.5 ± 0.3 for S aureus in vancomycin-loaded coatings, and 3.1 ± 0 for P aeruginosa for amikacin-loaded coatings (p < 0.001 for all comparisons of antibiotic-loaded coatings against uncoated controls for both bacterial strains, p < 0.001 for comparison of antibiotic-loaded coatings against phosphatidylcholine only for S aureus, p = 0.54 for comparison of vancomycin versus combination coating in S aureus, P = 0.99 for comparison of antibiotic- and unloaded phosphatidylcholine coatings in P aeruginosa). Similarly, antibiotic-loaded coatings reduced attachment of bacteria to wires in vivo (log-fold reduction of 2.54 ± 0; p < 0.001 for S aureus and 0.83 ± 0.3; p = 0.112 for P aeruginosa). CONCLUSIONS: Coatings deliver active antibiotics locally to inhibit biofilm formation and bacterial growth in vivo. Future evaluations will include orthopaedic preclinical models to confirm therapeutic efficacy. CLINICAL RELEVANCE: Clinical applications of local drug delivery coating could reduce the rate of implant-associated infections.
Authors: Peter A Norowski; Harry S Courtney; Jegdish Babu; Warren O Haggard; Joel D Bumgardner Journal: Implant Dent Date: 2011-02 Impact factor: 2.454
Authors: Jonathan R Pribaz; Nicholas M Bernthal; Fabrizio Billi; John S Cho; Romela Irene Ramos; Yi Guo; Ambrose L Cheung; Kevin P Francis; Lloyd S Miller Journal: J Orthop Res Date: 2011-08-11 Impact factor: 3.494
Authors: J Keaton Smith; Abteen R Moshref; Jessica A Jennings; Harry S Courtney; Warren O Haggard Journal: Clin Orthop Relat Res Date: 2013-04-20 Impact factor: 4.176
Authors: Heather A Doty; Megan R Leedy; Harry S Courtney; Warren O Haggard; Joel D Bumgardner Journal: J Mater Sci Mater Med Date: 2014-02-07 Impact factor: 3.896
Authors: Nicholas M Bernthal; Alexandra I Stavrakis; Fabrizio Billi; John S Cho; Thomas J Kremen; Scott I Simon; Ambrose L Cheung; Gerald A Finerman; Jay R Lieberman; John S Adams; Lloyd S Miller Journal: PLoS One Date: 2010-09-07 Impact factor: 3.240
Authors: Eleanor M Pritchard; Thomas Valentin; Bruce Panilaitis; Fiorenzo Omenetto; David L Kaplan Journal: Adv Funct Mater Date: 2012-09-26 Impact factor: 18.808
Authors: Katherine J Lauderdale; Cheryl L Malone; Blaise R Boles; Jose Morcuende; Alexander R Horswill Journal: J Orthop Res Date: 2010-01 Impact factor: 3.494
Authors: Suzanne Stewart; Stephanie Barr; Julie Engiles; Noreen J Hickok; Irving M Shapiro; Dean W Richardson; Javad Parvizi; Thomas P Schaer Journal: J Bone Joint Surg Am Date: 2012-08-01 Impact factor: 5.284
Authors: Allister J Loughran; Dana Gaddy; Karen E Beenken; Daniel G Meeker; Roy Morello; Haibo Zhao; Stephanie D Byrum; Alan J Tackett; James E Cassat; Mark S Smeltzer Journal: Infect Immun Date: 2016-08-19 Impact factor: 3.441
Authors: Joel M Berretta; Jessica A Jennings; Harry S Courtney; Karen E Beenken; Mark S Smeltzer; Warren O Haggard Journal: Clin Orthop Relat Res Date: 2017-07 Impact factor: 4.176
Authors: Daniel G Meeker; Karen E Beenken; Weston B Mills; Allister J Loughran; Horace J Spencer; William B Lynn; Mark S Smeltzer Journal: Antimicrob Agents Chemother Date: 2016-09-23 Impact factor: 5.191
Authors: Maria Magana; Christina Sereti; Anastasios Ioannidis; Courtney A Mitchell; Anthony R Ball; Emmanouil Magiorkinis; Stylianos Chatzipanagiotou; Michael R Hamblin; Maria Hadjifrangiskou; George P Tegos Journal: Clin Microbiol Rev Date: 2018-04-04 Impact factor: 26.132
Authors: Benjamin F Ricciardi; Gowrishankar Muthukrishnan; Elysia Masters; Mark Ninomiya; Charles C Lee; Edward M Schwarz Journal: Curr Rev Musculoskelet Med Date: 2018-09
Authors: Jessica Amber Jennings; Karen E Beenken; Robert A Skinner; Daniel G Meeker; Mark S Smeltzer; Warren O Haggard; Karen S Troxel Journal: World J Orthop Date: 2016-08-18